PHATHOM PHARMACEUTICALS, INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- PHATHOM PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $3.55M, a 4340.00% increase year-over-year.
- PHATHOM PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $591.00K.
- PHATHOM PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $293.00K, a 3.90% increase year-over-year.
- PHATHOM PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $80.00K, a 280.95% increase year-over-year.
- PHATHOM PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for fiscal 2025 was $1.64M, a 2.44% increase from fiscal 2024.
- PHATHOM PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for fiscal 2024 was $1.60M, a 1189.52% increase from fiscal 2023.
- PHATHOM PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for fiscal 2023 was $124.00K.
- PHATHOM PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for fiscal 2021 was $1.94M, a 209.06% increase from fiscal 2020.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $3.55M 10-Q · filed 2026-07-30 | |
| 2026-03-31 | $591.00K 10-Q · filed 2026-07-30 | |
| 2025-12-31 | $1.64M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $293.00K 10-Q · filed 2025-10-30 | |
| 2025-06-30 | $80.00K 10-Q · filed 2026-07-30 | |
| 2024-12-31 | $1.60M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $282.00K 10-Q · filed 2025-10-30 | |
| 2024-06-30 | $21.00K 10-Q · filed 2025-10-30 | |
| 2023-12-31 | $124.00K 10-K · filed 2025-03-06 | |
| 2023-09-30 | $13.00K 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $111.00K 10-Q · filed 2024-11-07 | |
| 2021-12-31 | $1.94M 10-K · filed 2023-02-28 | |
| 2021-09-30 | $1.26M 10-Q/A · filed 2022-11-09 | |
| 2021-06-30 | $104.00K 10-Q/A · filed 2022-11-09 | |
| 2021-03-31 | $412.00K 10-Q/A · filed 2022-11-09 | |
| 2020-12-31 | $629.00K 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 |